Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$1.20 ▼ -0.03
(-2.44%)
MKT CAP: $16.1M • VOL: 38.5K
52W L $1 52W H $5
ROARABLE / RQD
D- • 39/100
PIOTROSKI
3 / 9
PLUR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-06-30 | FY 2024
FILED 2024-06-30 | FY 2023
FILED 2023-06-30 |
|---|---|---|---|
| Revenue (Total Sales) | $1.3M | $326.0K | $287.0K |
| YoY Revenue Growth % | +309.8% | +13.6% | — |
| Gross Profit | $654.0K | $322.0K | — |
| Gross Margin % | 49.0% | 98.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$22.2M | -$22.2M | -$27.2M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$22.6M | $21.3M | $28.9M |
| EBITDA (Normalized) | -$20.9M | -$21.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$18.2M | -$18.0M | -$22.9M |
| Capital Expenditures (CapEx) | $1.6M | $323.0K | — |
| Free Cash Flow (FCF) | -$19.8M | -$18.3M | -$22.9M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $4.7M | $7.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$14.6M | -$8.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PLUR.